Variant misclassification emerges as key genomic testing risk

By AI, Created 1:21 PM UTC, May 26, 2026, /AGP/ – As clinical labs expand next-generation sequencing, variant misclassification is becoming a major operational and patient-safety problem. Golden Helix is positioning its VarSeq platform as a way to tighten interpretation, reporting and compliance as testing volumes rise.

Why it matters: - Variant misclassification can change patient care, family risk assessments and health system costs. - Studies tracking reclassification rates show 10% to 30% of variants are reclassified within three to five years of initial classification. - As genomic testing scales, the interpretation layer is becoming as important as sequencing hardware.

What happened: - Golden Helix said clinical genomics labs face a growing risk from variant misclassification as next-generation sequencing becomes a standard tool in medicine. - The company pointed to a widening infrastructure gap between sequencing investment and downstream interpretation workflows. - Golden Helix highlighted its VarSeq platform as a clinical genomics software system for variant classification, reporting and compliance. - More information is available on Golden Helix’s approach to clinical genomic interpretation.

The details: - Variant classification requires combining population frequency data, functional evidence, inheritance patterns and clinical case literature across thousands of variants per run. - Labs using manual workflows, disconnected databases or research-grade tools face higher risk as testing volumes increase. - Consequences can include delayed diagnosis, unnecessary clinical intervention and a duty to recontact patients when a variant is reclassified in some jurisdictions. - The risk is especially acute in targeted gene panel testing for hereditary cancer risk, cardiac disease and other inherited conditions. - Whole genome sequencing adds more complexity because manual interpretation does not scale well at production volume. - VarSeq includes structured ACMG and AMP classification workflows, monthly updated curated annotation databases, automated evidence gathering and clinical reporting built for CAP and CLIA compliance. - VarSeq supports targeted panels and whole genomes within a single validated environment. - Golden Helix is a clinical genomics software company headquartered in Bozeman, Montana. - The company said it has more than 25 years of experience and was founded in 1998. - Golden Helix said its software is used by genomics labs across North America, Europe and beyond.

Between the lines: - The market challenge is shifting from generating genomic data to interpreting it reliably at scale. - Labs that lack validated interpretation software may struggle to keep pace with regulatory expectations and reclassification obligations. - The emphasis on audit-ready reporting suggests compliance is becoming a competitive requirement, not just an administrative one.

What’s next: - More clinical labs are likely to prioritize interpretation software that can automate evidence review and support regulated workflows. - The next phase of NGS adoption may hinge on whether labs can make variant interpretation reproducible, reviewable and scalable. - Golden Helix is betting that clinical genome interpretation will be the next major upgrade area in genomic medicine.

The bottom line: - Sequencing is no longer the main bottleneck. Accurate variant interpretation is.